HomeGreater Than Icon
Mutual FundsGreater Than Icon
Compare Mutual FundsGreater Than Icon
Mirae Asset ELSS Tax Saver Fund - Direct (G) vs Nippon India Pharma Fund - Direct (G)

Mirae Asset ELSS Tax Saver Fund - Direct (G) vs Nippon India Pharma Fund - Direct (G)

stock1

Mirae Asset ELSS Tax Saver Fund - Direct (G)

5.72%

stock2

Nippon India Pharma Fund - Direct (G)

4.98%

Graph not available
Graph not available

About Fund

-

-

Deutsche Bank AG

Karvy Computershare Pvt. Ltd.

Very High Risk

500

22940.33

1.06

55.216

November 20, 2015

0

Very High Risk

5000

7898.24

1.12

587.3048

January 1, 2013

1

14.69 %

16.37 %

5.72 %

14.35 %

23.2 %

4.98 %

Neelesh Surana

B.E. (Mechanical), MBA (Finance)

Mr. Neelesh Surana is Head of Equities at Mirae Asset Global Investments (India) Pvt. Ltd. He joined Mirae Asset in 2008. In his capacity as Head of Equities, Neelesh spearheads the equity research and investment function. He is responsible for the managing existing equity funds of Mirae Asset (India), as well as, providing research support for the global mandate. Following others Schemes of the Fund are managed or co-managed by him: i. Mirae Asset India Opportunities Fund (to be renamed to 'Mirae Asset India Equity Fund' with effect from March 01, 2018), ii. Mirae Asset Prudence Fund (to be renamed as 'Mirae Asset Hybrid-Equity Fund' with effect from March 14, 2018) iii. Mirae Asset Tax Saver Fund iv. Mirae Asset Great Consumer Fund An engineering graduate with MBA in Finance, Neelesh has over 18 years of experience in equity research and portfolio management. Prior to Mirae, Neelesh was with ASK Investment Managers Ltd., as Senior Portfolio Manager responsible for managing domestic and international portfolios. a

Sailesh Raj Bhan

MBA (Finance), CFA.

Mr.Bhan is an MBA with specialization in Finance and CFA. Has over 9 Yrs. of experience in Equity Securities Research & Sequeir Investment Pvt. Ltd. for 5 years and with Emkay Share & stock Broker Pvt. Ltd. for 2 years.

Get your FAQs right

When comparing Mirae Asset ELSS Tax Saver Fund - Direct (G) vs Nippon India Pharma Fund - Direct (G), consider factors such as historical performance, expense ratios, investment strategy, risk level, and the fund manager's credibility. Moreover, look at asset allocation and how each fund fits your investment goals.
Yes, you can invest in both Mirae Asset ELSS Tax Saver Fund - Direct (G) and Nippon India Pharma Fund - Direct (G) at the same time. This can help diversify your portfolio and balance risk, provided the fund manager's investment strategies streamline each other.
While comparing Mirae Asset ELSS Tax Saver Fund - Direct (G) and Nippon India Pharma Fund - Direct (G), the portfolio turnover ratio indicates how frequently assets within the fund are bought and sold. A high turnover may lead to higher transaction costs and tax implications, while a low turnover ratio indicates a buy-and-hold strategy.
Yes, you can typically switch between Mirae Asset ELSS Tax Saver Fund - Direct (G) and Nippon India Pharma Fund - Direct (G), subject to the fund's policies and any applicable fees. It is important to consider potential tax implications and the timing of your switch.
Yes, you can compare Mirae Asset ELSS Tax Saver Fund - Direct (G) and Nippon India Pharma Fund - Direct (G) based on their dividend payouts. Look at dividends profit, consistency, and growth, as these factors can influence your overall return on investment.

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions